Dialog reaches valuation milestone and seeks trade sale
Dialog Devices Ltd has successfully developed and CE Marked VEWS® in Europe where it is approved ‘as an aid in the diagnosis of PAD’ and has a 510k application ready to file in the USA. The next exciting steps for VEWS® are European launch, regulatory clearance and launch in the USA and major markets globally, and development and launch of further products exploiting the VEWS® technology.
The Board of Dialog, following discussions with its shareholders and advisors, is now seeking a sale of the business to maximise the commercial return for VEWS®. Dialog offers an acquirer an excellent opportunity to purchase an innovative technology company including VEWS®, its IPR portfolio, patents, trademarks and know-how.
Contact Alan Edwards, Chairman for further information:
Dialog to present at 35th Charing Cross Symposium Vascular Meeting on 7th April 2013
For 35 years the Charing Cross (CX) Symposium has attracted thousands of vascular specialists to London. In 2013, CX 35 aims to continue this tradition with an update on the latest vascular and endovascular controversies to arise over the past few years. The CX symposium has garnered a loyal following of nearly 1200 vascular surgeons and in the last six years has attracted over 600 interventional radiologists and interventional cardiologists.
Dr Linda Summerton, Director of Dialog Devices will be showcasing Dialog's innovative device for evaluation of peripheral arterial disease and exploring commercial opportunities for this exciting technology.